Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma.

Trial Profile

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Marizomib (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Nereus Pharmaceuticals; Triphase Accelerator Corporation
  • Most Recent Events

    • 24 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Feb 2013 Actual end date changed from Mar 2009 to Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top